Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

ion upon the attainment of development and

regulatory milestones, plus additional undisclosed commercial milestone

payments.

-- Enrollment in CONNECTION, our confirmatory Phase 3 trial in

mild-to-moderate Alzheimer's disease, continues on track. All 30 of

our U.S. sites have been opened, and we expect the majority of our

ex-U.S. sites to be opened by the end of November. We expect to

complete enrollment of this trial in 2009.

-- Completed a randomized, double-blind safety and tolerability study of

combination therapy with Dimebon and donepezil (Aricept(R)) in patients

with Alzheimer's disease, which found the combination to be well

tolerated with no serious adverse events.

-- Plan to initiate new Phase 3 studies in 2009 to seek further

differentiation of Dimebon to include moderate-to-severe Alzheimer's

disease, adjunctive use with cholinesterase inhibitors, and

twelve-month efficacy.

-- Received a Corporate Achievement Award from the Huntington's Disease

Society of America (HDSA) for exemplifying leadership in the fight

against Huntington's disease and other neurodegenerative diseases.

-- Plan to initiate the next Huntington's disease efficacy study in 2009.

MDV3100: Drug candidate to treat castration-resistant prostate cancer

-- Presented data at the 20th EORTC-NCI-AACR Symposium on "Molecular

Targets and Cancer Therapeutics" from an ongoing open-label,

dose-escalation, U.S.-based Phase 1-2 clinical trial in prostate cancer

patients who have failed standard hormonal therapies. Results showed

encouraging and durable anti-tumor activity in the three expanded dose

groups tested thus far, as measured by prostate specific antigen (PSA)

declines, radiographic findings, circulating tumor cell (CTC) changes,

and time on treatment. MDV
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Pharmaco-Kinesis Corporation (PKC) announced today that ... Shutters on the Beach in Santa Monica, ... the Company,s innovative Metronomic Biofeedback Pump (MBP), a fully ... over time to a target site of the human ... system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
(Date:5/26/2015)... NEW YORK , May 26, 2015 ... NVGN ), announced today that it will present at the ... New York City at the Grand Hyatt ... Kelly , Novogen Chairman and CEO, is scheduled to begin at ... To access the webcast, go to http://wsw.com/webcast/marcum3/nvgn . ...
(Date:5/25/2015)... FL (PRWEB) May 26, 2015 Where ... speaker Jack Uldrich says, "The honest answer is that ... deliver four keynote speeches throughout the month of June, ... keynote topics vary from future-proofing to top tech trends. ... Uldrich's research is where the universe is expanding to. ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 2Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 3
... added four, six and eight port right-angle BNC connectors to its ... savings as a replacement for applications where a number of single ... ... Sunnyvale, CA (PRWEB) April 29, 2009 -- Regal Electronics ...
... - 4TB4Free , ... Austin, Texas (PRWEB) April 29, ... for accessing, storing and distributing content, today announced the release of ... can run virtual CAStor nodes in a single, physical server chassis. ...
... MEDX ) is scheduled to host a ... Time on Thursday, April 30, 2009 to review Medarex,s ... of 2009.To access the call live, please dial 1-877-397-0272 ... through the Investor Relations section of Medarex,s website at ...
Cached Biology Technology:Regal Introduces Four, Six and Eight Port Filtered and Un-Filtered Right Angle BNC Connectors 2Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009 2
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... Our immune system protects us from disease, destroying invading microbes with ... for no apparent reason, ganging up on normal tissues in our ... the immune system attacks the inner ear, home to the tiny, ... or weeks, patients lose the ability to hear in one or ...
... composition of the genetically produced potatoes known as fructan ... differ in the new substances intentionally incorporated with gene ... the Max Planck Institute of Molecular Plant Physiology and ... study published in the Proceedings of the National Academy ...
... a specific mechanism involved in the biology of malignant ... issue of Cancer Cell, significantly advance knowledge about epidermal ... cell surface receptor that stimulates cell growth by transmitting ... often present at abnormally elevated levels in human cancer ...
Cached Biology News:New Lab Research May Help Those Deafened By Immune System Attack 2New Lab Research May Help Those Deafened By Immune System Attack 3New Lab Research May Help Those Deafened By Immune System Attack 4A slight difference and significant similarities 2Physical and functional interaction of key cell growth molecules linked to cancer 2